Pacific Shuanglin Bio-pharmacy Co., Ltd.

Pacific Shuanglin Bio-pharmacy Co., Ltd. has seen a significant stock decline today, contrasting with a slight increase in the China Shanghai Composite. The company has faced ongoing financial challenges, including a notable drop in net sales and negative results over the past six quarters, raising concerns about its long-term outlook.

Pacific Shuanglin Bio-pharmacy Co., Ltd. faced a significant stock decline, reflecting ongoing challenges. The company reported a decrease in net sales and negative results for six consecutive quarters, with operating cash flow at a low. Its performance has consistently lagged behind the broader market index over multiple time frames.

Pacific Shuanglin Bio-pharmacy Co., Ltd. has faced significant challenges, with a 3.61% drop in stock price and a 27.65% decline over the past year. The company reports a continuous decrease in net sales and negative operating cash flow, indicating ongoing financial difficulties and a concerning long-term outlook.

Pacific Shuanglin Bio-pharmacy Co., Ltd. faced a significant decline on June 1, 2026, contrasting with the broader market's modest decrease. The company has reported a consistent drop in net sales and negative results for six quarters, alongside a troubling long-term performance and low operating cash flow, indicating ongoing challenges.

Pacific Shuanglin Bio-pharmacy Co., Ltd. saw a significant stock increase today, reaching an intraday high. However, the company faces long-term challenges, including a substantial yearly decline and negative financial results over six quarters. Its market capitalization is CNY 10,536 million, with a P/E ratio of 25.00.

Pacific Shuanglin Bio-pharmacy Co., Ltd. saw a notable increase in its stock price today, contrasting with a decline in the broader market. However, the company has struggled over the past year and three years, with significant declines in stock performance and mixed financial metrics, including negative operating cash flow.

Pacific Shuanglin Bio-pharmacy Co., Ltd. faced a notable decline in its stock today, reflecting ongoing challenges in its financial performance. The company has reported a significant drop in net sales and low operating cash flow, raising concerns about its market position within the pharmaceuticals and biotechnology sector.

Pacific Shuanglin Bio-pharmacy Co., Ltd. faced a significant stock decline, contrasting with broader market trends. The company reported a decrease in net sales and operating cash flow, alongside a modest return on capital employed. Over the past year, its stock has underperformed compared to the market, reflecting ongoing financial challenges.

Pacific Shuanglin Bio-pharmacy Co. experienced a notable stock price increase on February 26, 2026, reaching an intraday high. While the company has shown short-term gains, it faces longer-term challenges with a decline in net sales and negative performance over the past year, reflecting broader market dynamics.